All News

Study results show that intravenous immunoglobulin therapy can help combat this type of PRCA in individuals with anemia.

Teva Pharmaceutical Industries announced that fremanezumab can successfully reduce 2 common migraine comorbid symptoms—anxiety and depression.

Ronna Hauser, PharmD, and Bri Morris, PharmD, both from the National Community Pharmacists Association, discuss long-term care facilities and how they can make an impact on that patient population.

As individuals in a society, all people have implicit, or unconscious, beliefs that they have been socialized to hold; however, health care professionals’ implicit biases can impact patients’ lives.

Pharmacy Times will be spotlighting pharmacists throughout the month of October to recognize their contributions to the health care field.

October is Breast Cancer Awareness Month.

Phoenix-area Walgreens pharmacist Matthew Pruitt earns top honor as 2022 Pharmacist of the Year.

Empagliflozin has been found to lower the risk of death due to cardiovascular events and the number of first and recurrent heart failure hospitalizations.

Study results show that the frequency of adverse events decreased after the patients transitioned from combination therapy to monotherapy.

Indicated for the management of mild, moderate, and severe Alzheimer disease and dementia symptoms, the donepezil transdermal system (Adlarity; Corium) delivers donepezil hydrocholoride through the skin and is recommended at an initial dosage of 5 mg per day.

New research in immunotherapy is exploring vaccines to treat cancer, whether preventative or reactive against current tumors.

Douglas Hoey, CEO of NCPA, discusses NCPA's Annual Convention 2022, which will be held in Kansas City, Missouri from October 1 to October 4.

This month's generic product news features clorazepate dipotassium tablets, exemestane tablets, and paliperidone extended-release tablets.

Willoughby hopes on a global standpoint that every chronic condition patient has access to a support team that is there to provide care.

Belantamab mafodotin plus lenalidomide and dexamethasone was found tolerable with no new safety signals and enhanced response rates in patients with multiple myeloma.

All of the findings indicate that inadequate margin widths result in higher risks of distant recurrence and breast cancer mortality, as well as increased total recurrence.

The functional and physical well-being and other scores from the survey are more favorable for those who were treated with the therapy, investigators say.

A researcher discusses how developing tertiary lymphoid structures may reach a greater maturity level within the tumor microenvironment.

Given that dendritic cells are necessary for anti-tumor response, researchers investigated which pathways stop these cells from performing their full functions.

The incremental use of drug combinations could prevent hospitalizations from heart failure among those who have higher ejection farction, a subgroup that struggles with insufficient data on treatments.

Dupilumab is the first and only medicine approved specifically for the treatment of prurigo nodularis in the United States.

FDA revises emergency use authorization to grant prescribing authority for Pfizer’s Paxlovid antiviral treatment for COVID-19.

Despite significant advances in cancer treatment, molecular sequencing and enrollment of Black patients in clinical trials are still less than that of White and Asian patients.

Confidential care is a topic that is not discussed as frequently in healthcare, although it is extremely important for adolescents and different vulnerable communities.

Research suggests that HIV risk-reduction interventions could help adolescent males who are attracted to the same sex—and part of a minority ethnic and racial group—decrease HIV-risk sexual behaviors in the short-term.

Iheezo is a sterile, single use ophthalmic gel preparation.

Yvonne Chen, PhD, discusses her research to engineer more safe and effective next-generation CAR-T therapy for cancer immunotherapy.

Expert discusses whether epigenetic programs regulate human T cell exhaustion and whether epigenetic-based strategies can be used to enhance T cell-based therapies.

Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Two Houston Methodist cancer researchers were granted a quarter of a million dollars each to study some of the most lethal cancers.